Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 309

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 19
Chunk 309
---
 dividing (x) the product of the number of Ordinary shares underlying the warrants, multiplied by the excess of the “fair market
value” of Ordinary shares over the exercise price of the warrants by (y) the fair market value. The “fair market value”
will mean the average closing price of the Ordinary shares for the10trading days ending on the third trading day prior to the date on
which the notice of redemption is sent to the holders of warrants.

Private Warrants

Except as described below, the Private
Warrants have terms and provisions that are identical to those of the Public Warrants.

The Private Warrants will not be redeemable
by the combined company so long as they are held by the Sponsor or its permitted transferees. The Sponsor, or its permitted transferees,
has the option to exercise the Private Warrants on a cashless basis. If the Private Warrants are held by someone other than the Sponsor
or its permitted transferees, the Private Warrants will be redeemable by the combined company and exercisable by such holders on the same
basis as the Public Warrants. If holders of the Private Warrants elect to exercise them on a cashless basis, they would pay the exercise
price by surrendering their warrants for that number of Ordinary shares equal to the quotient obtained by dividing (x) the product of
the number of shares of Ordinary shares underlying the warrants, multiplied by the difference between the exercise price of the warrants
and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” means the average
reported last sale price of the Ordinary shares for the10trading days ending on the third trading day prior to the date on which the
exercise notice is sent to the warrant agent.

F-21

ALPHA TAU MEDICAL
LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS

U. S. dollars
in thousands (except share and per share data)

NOTE 9:- FAIR
VALUE MEASUREMENTS

The
following table presents information about the Company’s liabilities that are measured at fair value on a recurring basis as of
December 31, 2023 and 2024 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such
fair value:

                                            December 31, 2023                                                
                                            Level 1                           Level 2      Level 3           
  Warrants liability